HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leuchte, H. H. Articles by Behr, J. Search for Related Content PubMed PubMed Citation Articles by Leuchte, H. H. Articles by Behr, J.

Inhalation of vasoactive intestinal peptide in pulmonary hypertension

¹ Division of Pulmonary Diseases, Dept of Internal Medicine I, Ludwig Maximilians University, Klinikum Grosshadern, Munich, Germany, and ² mondoBIOTECH, Basel, Switzerland.

CORRESPONDENCE: H. H. Leuchte, Division of Pulmonary Diseases, Dept of Internal Medicine I, Ludwig Maximilians University, Klinikum Grosshadern, Marchioninistr. 15, 81377 Munich, Germany. Fax: 49 8970958877. E-mail: Hanno.Leuchte{at}med.uni-muenchen.de

Keywords: Heart failure, hypertension, peptides, pulmonary, vasodilation

Received: March 31, 2008
Accepted July 28, 2008

Pulmonary hypertension (PH) leads to an increased right ventricular workload, cardiac failure and death. In idiopathic pulmonary arterial hypertension (PAH) the vasodilating vasoactive intestinal peptide (aviptadil) is deficient. The aim of the present study was to test the acute effects on haemodynamics and blood gases, and the safety, of a single dose of inhaled aviptadil in chronic PH.

A total of 20 patients with PH (PAH in nine, PH in lung disease in eight and chronic thromboembolic PH in three) inhaled a single 100-µg dose of aviptadil during right-heart catheterisation. Haemodynamics and blood gases were measured.

Aviptadil aerosol caused a small and temporary but significant selective pulmonary vasodilation, an improved stroke volume and mixed venous oxygen saturation. Overall, six patients experienced a pulmonary vascular resistance reduction of >20%. In patients with significant lung disease, aviptadil tended to improve oxygenation.

The pulmonary vasodilating effect of aviptadil aerosol was modest and short-lived, did not cause any side-effects and led to a reduced workload of the right ventricle without affecting systemic blood pressure. Aviptadil inhalation tended to improve oxygenation in patients with significant lung disease. Further studies are needed to evaluate the full therapeutic potential of aviptadil aerosol, including higher doses and chronic treatment.

This article has been cited by other articles:

				D. Vaudry, A. Falluel-Morel, S. Bourgault, M. Basille, D. Burel, O. Wurtz, A. Fournier, B. K. C. Chow, H. Hashimoto, L. Galas, et al. Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery Pharmacol. Rev., September 1, 2009; 61(3): 283 - 357. [Abstract] [Full Text] [PDF]